STATEMENTS OF CHANGES IN STOCKHOLDERS DEFICIT - USD ($)	Total	Common Stock	Series A, Preferreds Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2022		13,439,789	2,000
Balance, amount at Dec. 31, 2022	$ (1,279,282)	$ 1,344	$ 2	$ 8,254,316	$ (9,534,944)
Issuance of common stock for note amendment, shares		150,000
Issuance of common stock for note amendment, amount	52,500	$ 15		52,485
Stock award, shares		60,000
Stock award, amount	16,680	$ 6		16,674
Stock options granted to non-employees as consulting fees	45,811			45,811
Stock options granted to non-employees as research and development costs	465,345			465,345
Net loss for the year	(789,347)				(789,347)
Balance, shares at Dec. 31, 2023		13,649,789	2,000
Balance, amount at Dec. 31, 2023	(1,488,293)	$ 1,365	$ 2	8,834,631	(10,324,291)
Issuance of common stock for note amendment, shares		300,000
Issuance of common stock for note amendment, amount	55,644	$ 30		55,614
Stock award, shares		100,000
Stock award, amount	18,300	$ 10		18,290
Stock options granted to non-employees as consulting fees	11,406			11,406
Stock options granted to non-employees as research and development costs	142,396			142,396
Net loss for the year	(56,097)				(56,097)
Derivative liability associated with warrants under convertible note amended	233,365			233,365
Issuance of common stock for debt settlement, shares		3,043,716
Issuance of common stock for debt settlement, amount	557,000	$ 304		556,696
Issuance of common stock as financing fee, shares		88,000
Issuance of common stock as financing fee, amount	16,104	$ 9		16,095
Warrants exercised associated with License and Research Funding Agreement, shares		418,494
Warrants exercised associated with License and Research Funding Agreement, amount	65,327	$ 42		65,285
Balance, shares at Dec. 31, 2024		17,599,999	2,000
Balance, amount at Dec. 31, 2024	$ (444,848)	$ 1,760	$ 2	$ 9,933,778	$ (10,380,388)